New drug aims to lower dangerous blood fats in High-Risk patients
NCT ID NCT06797401
First seen Oct 01, 2025 · Last updated Apr 30, 2026 · Updated 26 times
Summary
This study tests an experimental drug called RBD5044 in 120 adults with mixed dyslipidemia, a condition where blood fat levels are too high. Participants will receive either the drug or a placebo twice over 12 months to see if it safely lowers triglycerides. The goal is to control the disease and reduce heart risk, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Akademiska Sjukhuset Uppsala
RECRUITINGUppsala, Sweden
Contact
-
AkardoMedSite
RECRUITINGStockholm, Sweden
Contact
-
Lunds Universitetssjukhus
RECRUITINGLund, Sweden
Contact
-
Ribocure Clinic/Ribocure Pharmaceuticals AB
RECRUITINGMölndal, Sweden
Contact
Conditions
Explore the condition pages connected to this study.